

West Virginia Medicaid Drug Utilization Review Board Minutes

September 25, 2019

The West Virginia Medicaid Drug Utilization Review (DUR) Board meeting was called to order with the following in attendance;

Members:

Lester Labus, MD, Chair
K.C. Lovin, PA-C, Vice Chair
C.K. Babcock, PharmD
Chris Booth, PharmD
Scott Brown, RPh
Myra Chiang, MD
Phillip Galapon, MD
David Gloss, MD
Michael Lonsinger, PharmD
Ernest Miller, DO
Mary Nemeth-Pyles, MSN, RN, CS
Christopher Terpening, PharmD, PhD
John Vanin, MD

Members Absent:

Michael Ballow, PharmD
Kate Forman, PharmD

DHHR/BMS Staff:

Brian Thompson, MS, PharmD, Director of Pharmacy Services
Lori Moles, RPh, Staff Pharmacist
Bill Hopkins, Pharmacy operations Manager
Doug Sorvig, Administrative Assistant

Contract Staff:

Chris Hale, PharmD, Rational Drug Therapy Program (RDTP)
Alesha Heil, PharmD, SEMP
Rob Stanton, PharmD, Marshall University
Kim Broedel-Zaugg, RPh, PhD, Marshall University
Sarah Plummer, PharmD, Marshall University
Eric Sears, RPh, DXC
Brent Breeding, RPh, Change Healthcare

I. INTRODUCTIONS

- a. Dr. Lester Labus, Chair, welcomed everyone to the Board meeting at 4:02pm EDT. The DUR Board and attendees introduced themselves.

II. APPROVAL OF MINUTES FROM September 25, 2019 DUR BOARD MEETING

- a. A motion was made, seconded, and approved to accept the minutes from the previous DUR meeting.

III. OLD BUSINESS

- a. The nominations committee met and presented the following slate:
 - Chair: KC Lovin
 - Vice Chair: Chris TerpeningNo nominations were received from the floor. A motion was made to accept the slate. Motion approved.

IV. NEW BUSINESS

- a. **Speakers**
 - i. none
- b. **Updates from August 28, 2019 P & T Committee Meeting**
 - i. Mr. Breeding presented the updates from the October 30, 2019 P & T meeting for board review. No changes were requested.
- c. **PDL Prior Authorization Criteria.** Attachment A
 - i. **Hemlibra:** approved as presented.
 - ii. **Sunosi:** approved as presented.
 - iii. **Cytokine agents – Acitretin for plaque psoriasis:** approved as presented.
 - iv. **CGRP Antagonists:** approved as presented.
 - v. **Testosterone Replacement Therapy:** approved as presented.
 - vi. **Atypical Antipsychotics- Latuda:** approved as presented.
 - vii. **Orlissa:** approved as amended. NSAID use may be documented. Patient has failed a 90-day trial of each of the following: a) GnRH agonist and b) an extended-cycle combined oral contraceptive OR progestin therapy.
 - viii. **MS Agents:** approved as presented.
 - ix. **PCSK9 inhibitors:** approved as presented.
 - x. **Zetia:** approved as presented.
 - xi. **Linzess:** approved as presented.
 - xii. **Motegrity:** approved as presented
 - xiii. **Ophthalmics, anti-inflammatories-immunomodulators:** approved as amended. Multiple dose containers must be approved on appeal
 - xiv. **Rho-kinase inhibitors:** approved as presented.
 - xv. **Fasenra:** approved as presented.
 - xvi. **Trikafta:** approved as presented.

V. REPORTS

- a. **DXC Quarterly Report:** Mr. Sears presented an overview of the 2019 Third Quarter Report which included a review of the DUR Quarterly Overall Summary Report. Attachment B.
- b. **Rational Drug Therapy Program:** Dr. Hale presented a review of the prior authorization program for the Third Quarter of 2019. Attachment C
- c. **Marshall University Coalition:** Dr. Stanton reported on the progress of retro DUR, the lock in program, and number of letters sent/returned. Attachment D

VI. OTHER BUSINESS

- a. none

VII. NEXT MEETING AND ADJOURNMENT

- VIII.**
- a.** A motion to adjourn the meeting was made, seconded, and approved.
 - b.** The meeting concluded at 5:32pm EDT.
 - c.** The next meeting will be February 19, 2020 from 4:00pm to 6:00pm and located at WVDHHR.